| CD4+ (cells/mm3) | 50 mg ABX464
(total=6) |
150 mg ABX464
(total=16) |
Placebo
(total=8) |
Difference in LS means: 150 mg vs placebo (95% CI) | P value | |
|---|---|---|---|---|---|---|
| Day 0 | n | 6 | 16 | 8 | ||
| Mean (SD) | 1004.8 (201.7) | 926.4 (394.6) | 698.0 (179.8) | |||
| Median [Range] | 982.0 [800–1340] | 784.5 [426–1792] | 681.5 [448–998] | |||
| LS mean | 926.4 | 698.0 | 228.4 (-78.1–534.8) | 0.1365 | ||
| Day 7 | n | 6 | 16 | 7 | ||
| Mean (SD) | 964.8 (258.8) | 795.4 (268.8) | 815.9 (387.8) | |||
| Median [Range] | 949.0 [630–1377] | 758.0 [392–1290] | 616.0 [527–1591] | |||
| LS mean | 795.4 | 815.9 | -20.4 (-310.3–269.4) | 0.8849 | ||
| Day 14 | n | 5 | 15 | 7 | ||
| Mean (SD) | 1119.0 (350.4) | 846.6 (289.2) | 786.4 (406.8) | |||
| Median [Range] | 970.0 [780–1571] | 800.0 [506–1419] | 575.0 [511–1628] | |||
| LS mean | 846.6 | 786.4 | 60.2 (-253.9–374.2) | 0.6937 | ||
| Day 21 | n | 6 | 15 | 8 | ||
| Mean (SD) | 999.7 (358.0) | 786.5 (293.5) | 834.6 (368.8) | |||
| Median [Range] | 973.0 [520–1602] | 740.0 [415–1337] | 663.5 [547–1665] | |||
| LS mean | 786.5 | 834.6 | -48.2 (-340.0–243.7) | 0.7349 | ||
| Day 25 | n | 3 | 9 | 6 | ||
| Mean (SD) | 1089.7 (174.0) | 942.1 (284.2) | 816.7 (306.7) | |||
| Median [Range] | 1089.0 [916–1264] | 926.0 [518–1487] | 756.0 [401–1282] | |||
| LS mean | 942.1 | 816.7 | 125.4 (-208.2–459.1) | 0.4313 | ||
| Day 28 | n | 6 | 13 | 6 | ||
| Mean (SD) | 987.2 (304.1) | 853.4 (291.2) | 838.2 (339.3) | |||
| Median [Range] | 864.5 [728–1516] | 770.0 [494–1480] | 688.0 [612–1491] | |||
| LS mean | 853.4 | 838.2 | 15.2 (-303.5, 334.0) | 0.9209 | ||
n: number of participants; SD: standard deviation; LS mean: least squares mean; CI: confidence interval.
Viral load analysed using an analysis of variance (ANOVA) model with treatment as a fixed effect.